Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

Table 6 Univariate and multivariate Cox analysis of prognostic factors in microsatellite stable metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy

Dependent: Survival (PFS/30, status)		All	HR (univariable)	HR (multivariable)
Age	> 60	11 (44.0)	-	-
	≤ 60	14 (56.0)	0.20 (0.07-0.62, P = 0.005)	0.27 (0.05-1.48, P = 0.133)
Gender	Male	18 (72.0)	-	-
	Female	7 (28.0)	1.01 (0.40-2.54, P = 0.979)	-
ECOG	1	21 (84.0)	-	-
	2	4 (16.0)	1.01 (0.23-4.55, P = 0.985)	-
Location	Right colon	9 (36.0)	-	-
	Left colon and rectum	16 (64.0)	0.73 (0.31-1.74, P = 0.477)	-
Liver metastasis	No	7 (28.0)	-	-
	Yes	18 (72.0)	5.23 (1.48-18.50, P = 0.010)	8.15 (1.39-47.83, P = 0.020)
Lung metastasis	No	10 (40.0)	-	-
	Yes	15 (60.0)	0.62 (0.25-1.51, P = 0.291)	-
RAS mutation type	Unknown	5 (20.0)	-	-
	Wild type	3 (12.0)	0.75 (0.13-4.20, P = 0.742)	-
	Mutation	17 (68.0)	2.30 (0.74-7.14, P = 0.151)	-
CEA	Normal	6 (24.0)	-	-
	Abnormal	19 (76.0)	0.59 (0.21-1.67, P = 0.316)	-
CA199	Normal	13 (52.0)	-	-
	Abnormal	12 (48.0)	3.16 (1.12-8.88, P = 0.029)	1.06 (0.23-4.90, P = 0.942)
NLR	≤ 2.9	13 (52.0)	-	-
	> 2.9	12 (48.0)	1.45 (0.60-3.55, P = 0.410)	-
LMR	≤ 3.63	13 (52.0)	-	-
	> 3.63	12 (48.0)	0.57 (0.23-1.39, P = 0.216)	-
PLR	≤ 121	13 (52.0)	-	-
	> 121	12 (48.0)	1.43 (0.58-3.48, P = 0.436)	-
BMI	≤ 24.9	12 (48.0)	-	-
	> 24.9	13 (52.0)	1.02 (0.43-2.42, P = 0.963)	-
ALI	≤ 260.9	13 (52.0)	-	-
	> 260.9	12 (48.0)	0.30 (0.10-0.85, P = 0.023)	0.50 (0.15-1.64, P = 0.252)
SII	≤ 426.8	13 (52.0)	-	-
	> 426.8	12 (48.0)	1.74 (0.72-4.25, P = 0.220)	-
ALLC	≤ 6.0	13 (52.0)	-	-
	> 6.0	12 (48.0)	1.31 (0.53-3.20, P = 0.559)	-
ANC	≤ 4.1	13 (52.0)	-	-
	> 4.1	12 (48.0)	1.31 (0.53-3.20, P = 0.559)	-
ALC	≤ 1.4	13 (52.0)	-	-
	> 1.4	12 (48.0)	0.61 (0.25-1.50, P = 0.285)	-
AMC	≤ 0.4	13 (52.0)	-	-
	> 0.4	12 (48.0)	0.71 (0.28-1.82, P = 0.473)	-
AEC	≤ 0.2	13 (52.0)	-	-
	> 0.2	12 (48.0)	1.59 (0.65-3.89, P = 0.309)	-
RDW	≤ 15.2	13 (52.0)	-	-
	> 15.2	12 (48.0)	1.04 (0.42-2.57, P = 0.938)	-
LDH	≤ 240.0	13 (52.0)	-	-
	> 240.0	12 (48.0)	3.09 (1.16-8.22, P = 0.024)	5.72 (1.58-20.72, P = 0.008)

n = 25, events = 21, likelihood ratio test = 25.81 on 5 df (P < 0.001). ECOG: Eastern Cooperative Oncology Group; PFS: Progression-free survival; HR: Hazard ratio; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; NLR: Neutrophil-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; PLR: Platelet-to-lymphocyte ratio; BMI: Body mass index; ALI: Advanced lung cancer inflammation index; SII: Systemic immune-inflammation index; ALLC: Absolute leukocyte count; ANC: Absolute neutrophil count; ALC: Absolute lymphocyte count; AMC: Absolute monocyte count; AEC: Absolute eosinophil count; RDW: Red blood cell distribution width; LDH: Lactate dehydrogenase.